高流量鼻导管氧疗与标准氧疗对COVID-19呼吸衰竭患者死亡率的影响:SOHO-COVID随机临床试验
SOHO-COVID随机临床试验在法国34个ICU纳入711例COVID-19呼吸衰竭且PaO2/FiO2≤200 mmHg的患者,比较高流量鼻导管氧疗(357例)与标准氧疗(354例)。第28天死亡率高流量组10%(36/357) vs 标准氧疗组11%(40/354),绝对差-1.2%(95%CI -5.8%至3.4%;P=0.60),无显著差异;插管率显著降低(45% vs 53%;绝对差-7.7%;95%CI -14.9%至-0.4%;P=0.04)。
要点
- 在COVID-19呼吸衰竭患者中,高流量鼻导管氧疗相比标准氧疗未显著降低第28天死亡率。
- 高流量氧疗组插管率显著低于标准氧疗组(45% vs 53%;绝对差-7.7%;95%CI -14.9%至-0.4%;P=0.04)。
- 13项预设次要结局中12项无显著差异,包括ICU住院时间和死亡率、第90天死亡率。
核心结论
- 在COVID-19所致呼吸衰竭患者中,与标准氧疗相比,高流量鼻导管氧疗未显著降低第28天死亡率。
研究设计与样本
- SOHO-COVID随机临床试验,在法国34个ICU开展,纳入711例COVID-19呼吸衰竭且PaO2/FiO2≤200 mmHg的患者(平均[SD]年龄61[12]岁;女性214例[30%])。
- 患者随机分配至高流量氧疗组(n=357)或标准氧疗组(n=354,经非重复呼吸面罩,初始最低设定10 L/min)。
- 患者入组时间为2021年1月至12月;最终随访于2022年3月5日完成。
主要发现
- 第28天死亡率:高流量氧疗组10%(36/357) vs 标准氧疗组11%(40/354);绝对差-1.2%(95%CI -5.8%至3.4%;P=0.60),无显著差异。
- 插管率:高流量氧疗组45%(160/357) vs 标准氧疗组53%(186/354);绝对差-7.7%(95%CI -14.9%至-0.4%;P=0.04),高流量组显著低于标准氧疗组。
- 第28天无呼吸机天数:高流量氧疗组中位数28天(IQR 11-28) vs 标准氧疗组23天(IQR 10-28);绝对差0.5天(95%CI -7.7至9.1;P=0.07),无显著差异。
- 13项预设次要结局中12项无显著差异,包括ICU住院时间和死亡率、第90天死亡率。
- 最常见不良事件为呼吸机相关性肺炎:高流量氧疗组58%(93/160) vs 标准氧疗组53%(99/186)。
关键数值与推荐
- 第28天死亡率绝对差-1.2%(95%CI -5.8%至3.4%;P=0.60),未达统计学显著。
- 插管率绝对差-7.7%(95%CI -14.9%至-0.4%;P=0.04),高流量氧疗组显著低于标准氧疗组。
- 第28天无呼吸机天数绝对差0.5天(95%CI -7.7至9.1;P=0.07),未达统计学显著。
临床怎么用
- 原文结论为在COVID-19呼吸衰竭患者中高流量鼻导管氧疗相比标准氧疗未显著降低第28天死亡率,原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The benefit of high-flow nasal cannula oxygen (high-flow oxygen) in terms of intubation and mortality in patients with respiratory failure due to COVID-19 is controversial. OBJECTIVE: To determine whether the use of high-flow oxygen, compared with standard oxygen, could reduce the rate of mortality at day 28 in patients with respiratory failure due to COVID-19 admitted in intensive care units (ICUs). DESIGN, SETTING, AND PARTICIPANTS: The SOHO-COVID randomized clinical trial was conducted in 34 ICUs in France and included 711 patients with respiratory failure due to COVID-19 and a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen equal to or below 200 mm Hg. It was an ancillary trial of the ongoing original SOHO randomized clinical trial, which was designed to include patients with acute hypoxemic respiratory failure from all causes. Patients were enrolled from January to December 2021; final follow-up occurred on March 5, 2022. INTERVENTIONS: Patients were randomly assigned to receive high-flow oxygen (n = 357) or standard oxygen delivered through a nonrebreathing mask initially set at a 10-L/min minimum (n = 354). MAIN OUTCOMES AND MEASURES: The primary outcome was mortality at day 28. There were 13 secondary outcomes, including the proportion of patients requiring intubation, number of ventilator-free days at day 28, mortality at day 90, mortality and length of stay in the ICU, and adverse events. RESULTS: Among the 782 randomized patients, 711 patients with respiratory failure due to COVID-19 were included in the analysis (mean [SD] age, 61 [12] years; 214 women [30%]). The mortality rate at day 28 was 10% (36/357) with high-flow oxygen and 11% (40/354) with standard oxygen (absolute difference, -1.2% [95% CI, -5.8% to 3.4%]; P = .60). Of 13 prespecified secondary outcomes, 12 showed no significant difference including in length of stay and mortality in the ICU and in mortality up until day 90. The intubation rate was significantly lower with high-flow oxygen than with standard oxygen (45% [160/357] vs 53% [186/354]; absolute difference, -7.7% [95% CI, -14.9% to -0.4%]; P = .04). The number of ventilator-free days at day 28 was not significantly different between groups (median, 28 [IQR, 11-28] vs 23 [IQR, 10-28] days; absolute difference, 0.5 days [95% CI, -7.7 to 9.1]; P = .07). The most common adverse events were ventilator-associated pneumonia, occurring in 58% (93/160) in the high-flow oxygen group and 53% (99/186) in the standard oxygen group. CONCLUSIONS AND RELEVANCE: Among patients with respiratory failure due to COVID-19, high-flow nasal cannula oxygen, compared with standard oxygen therapy, did not significantly reduce 28-day mortality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04468126.
引用
- Frat JP, Quenot JP, Badie J, et al. Effect of High-Flow Nasal Cannula Oxygen vs Standard Oxygen Therapy on Mortality in Patients With Respiratory Failure Due to COVID-19: The SOHO-COVID Randomized Clinical Trial. JAMA. 2022. PMID: 36166027. doi:10.1001/jama.2022.15613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。